Innovating Works

WMU

ExoDiagAI: Empowering Personalized Therapeutics: Advancing 3D-Nano DLD Arrays and Raman Micro-Biochips for Prec... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 The ExoDiagAI project is at the forefront of addressing a critical challenge in modern healthcare—early diagnosis and effective management o...
2024-05-14 - 2026-07-14 | Financiado
ETUDE: Encompassing Training in fUnctional Disorders across Europe UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-MSCA-ITN-2020 Functional Disorders (FD) are clusters of chronic somatic symptoms that currently cannot be associated to reproducibly observable pathophysi...
2020-09-04 - 2024-12-31 | Financiado
HEARTBIT_4.0: HeartBIT 4.0 Application of innovative Medical Data Science technologies for heart diseases. UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU tramitó un H2020: H2020-WIDESPREAD-2018-2020 Support of medical care requires new skills related to effective control of applied medication and methods of treatment, elimination of mutu...
2019-07-11 - 2022-12-31 | Financiado
ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado
REGIONS4PERMED: INTERREGIONAL COORDINATION FOR A FAST AND DEEP UPTAKE OF PERSONALISED HEALTH UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-SC1-BHC-2018-2020 Personalised medicine (PM) represents a paradigm shift away from a ‘one size fits all’ approach to the treatment and care of patients with a...
2018-10-19 - 2023-04-30 | Financiado
RECOMB: Stem cell based gene therapy for recombination deficient SCID RECOMB UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-SC1-2016-2017 Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SC...
2017-11-21 - 2024-12-31 | Financiado
BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado
SECURE: Secondary prEvention of CardiovascUlaR disease in the Elderly trial UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020: H2020-PHC-2014-2015 While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overal...
2015-04-08 - 2021-12-31 | Financiado
SICA-HF: Studies Investigating Co morbidities Aggravating Heart Failure UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7: Chronic heart failure (CHF) is a massive clinical, social and economic problem. Diabetes and obesity increase the risk of developing CHF. Ca...
Financiado
BIOELECTRICSURFACE: Electrically modified biomaterials surface UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7: According to the World Health Organisation (WHO), cardiovascular diseases cause half the deaths in the EU. It is also the main cause of year...
Financiado
INTREALL: International study for treatment of childhood relapsed ALL 2010 with standard therapy systematic i... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7: Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood...
Financiado
BIOSTAT-CHF: A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7: Heart failure is common in Europe and its prevalence is increasing as our population ages. Despite major improvements in care since the earl...
Financiado
EPICSTENT: Antibody functionalised cardiovascular stents for improved biocompatibility and reduced restenosis UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7: An industry-academia collaboration is proposed wherein two industry and three academic partners will establish a lasting, inter-national par...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.